nach oben

Erschienen in:

02.07.2019 | Preclinical study

Infiltration by myeloperoxidase-positive neutrophils is an independent prognostic factor in breast cancer

verfasst von: Jasmin Zeindler, Fiorenzo Angehrn, Raoul Droeser, Silvio Däster, Salvatore Piscuoglio, Charlotte K. Y. Ng, Ergin Kilic, Robert Mechera, Samuel Meili, Andrej Isaak, Walter P. Weber, Simone Muenst, Savas Deniz Soysal

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Myeloperoxidase (MPO) is an enzyme secreted by neutrophil granulocytes as a result of phagocytosis during inflammation. In colorectal cancer, tumour infiltration by MPO expressing cells has been shown to be independently associated with a favourable prognosis. In this study, we explored the role of MPO-positive cell infiltration and its prognostic significance in invasive breast cancer.

Methods

We performed immunohistochemical staining for MPO on multiple tissue microarrays comprising a total of 928 human breast cancer samples with detailed clinical-pathological annotation and outcome data.

Results

MPO-positive cell infiltration (≥ 5 cells/tissue punch) was found in 150 (16%) of the 928 evaluable breast cancer cases. In univariate survival analyses, infiltration by MPO-positive cells was associated with a significantly better overall survival (p < 0.001). In subset univariate analyses, the infiltration by MPO-positive cells was associated with significantly better overall survival in the Luminal B/HER2-negative subtype (p = 0.005), the HER2 enriched subtype (p = 0.011), and the Triple Negative subtype (p < 0.001). In multivariate analysis, MPO expression proved to be an independent prognostic factor for improved overall survival (p < 0.001).

Conclusions

This is the first study to show that infiltration of MPO-positive cells is an independent prognostic biomarker for improved overall survival in human breast cancer.

Siegel RL, Miller KD, Jemal A (2017) Cancer statistics. CA Cancer J Clin 67(1):7–30. https://doi.org/10.3322/caac.21387 CrossRefPubMed

Tong CWS, Wu M, Cho WCS, To KKW (2018) Recent advances in the treatment of breast cancer. Front Oncol 8:227. https://doi.org/10.3389/fonc.2018.00227 CrossRefPubMedPubMedCentral

Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu A, Hallett M, Park M (2008) Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14(5):518–527. https://doi.org/10.1038/nm1764 CrossRefPubMed

Hu M, Yao J, Cai L, Bachman KE, van den Brule F, Velculescu V, Polyak K (2005) Distinct epigenetic changes in the stromal cells of breast cancers. Nat Genet 37(8):899–905. https://doi.org/10.1038/ng1596 CrossRefPubMed

Soysal SD, Tzankov A, Muenst SE (2015) Role of the tumor microenvironment in breast cancer. Pathobiology 82(3–4):142–152. https://doi.org/10.1159/000430499 CrossRefPubMed

Gregory AD, Houghton AM (2011) Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res 71(7):2411–2416. https://doi.org/10.1158/0008-5472.CAN-10-2583 CrossRefPubMed

Fridlender ZG, Albelda SM (2012) Tumor-associated neutrophils: friend or foe? Carcinogenesis 33(5):949–955. https://doi.org/10.1093/carcin/bgs123 CrossRefPubMed

Shen M, Hu P, Donskov F, Wang G, Liu Q, Du J (2014) Tumor-associated neutrophils as a new prognostic factor in cancer: a systematic review and meta-analysis. PLoS ONE 9(6):e98259. https://doi.org/10.1371/journal.pone.0098259 CrossRefPubMedPubMedCentral

Soto-Perez-de-Celis E, Chavarri-Guerra Y, Leon-Rodriguez E, Gamboa-Dominguez A (2017) Tumor-associated neutrophils in breast cancer subtypes. Asian Pac J Cancer Prev 18(10):2689–2693. https://doi.org/10.22034/APJCP.2017.18.10.2689 CrossRefPubMedPubMedCentral

10.

Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, Worthen GS, Albelda SM (2009) Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell 16(3):183–194. https://doi.org/10.1016/j.ccr.2009.06.017 CrossRefPubMedPubMedCentral

11.

Klebanoff SJ (2005) Myeloperoxidase: friend and foe. J Leukoc Biol 77(5):598–625. https://doi.org/10.1189/jlb.1204697 CrossRefPubMed

12.

Winterbourn CC, Vissers MC, Kettle AJ (2000) Myeloperoxidase. Curr Opin Hematol 7(1):53–58CrossRefPubMed

13.

Hampton MB, Kettle AJ, Winterbourn CC (1998) Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing. Blood 92(9):3007–3017CrossRefPubMed

14.

Kato Y (2016) Neutrophil myeloperoxidase and its substrates: formation of specific markers and reactive compounds during inflammation. J Clin Biochem Nutr 58(2):99–104. https://doi.org/10.3164/jcbn.15-104 CrossRefPubMedPubMedCentral

15.

Tatsumi T, Fliss H (1994) Hypochlorous acid and chloramines increase endothelial permeability: possible involvement of cellular zinc. Am J Physiol 267(4 Pt 2):H1597–H1607. https://doi.org/10.1152/ajpheart.1994.267.4.H1597 CrossRefPubMed

16.

McKenzie SJ, Baker MS, Buffinton GD, Doe WF (1996) Evidence of oxidant-induced injury to epithelial cells during inflammatory bowel disease. J Clin Invest 98(1):136–141. https://doi.org/10.1172/JCI118757 CrossRefPubMedPubMedCentral

17.

Rodriguez PC, Quiceno DG, Zabaleta J, Ortiz B, Zea AH, Piazuelo MB, Delgado A, Correa P, Brayer J, Sotomayor EM, Antonia S, Ochoa JB, Ochoa AC (2004) Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 64(16):5839–5849. https://doi.org/10.1158/0008-5472.CAN-04-0465 CrossRefPubMed

18.

Vile GF, Rothwell LA, Kettle AJ (1998) Hypochlorous acid activates the tumor suppressor protein p53 in cultured human skin fibroblasts. Arch Biochem Biophys 359(1):51–56. https://doi.org/10.1006/abbi.1998.0881 CrossRefPubMed

19.

Naito Y, Yoshikawa T, Fujii T, Boku Y, Yagi N, Dao S, Yoshida N, Kondo M, Matsui H, Ohtani-Fujita N, Sakai T (1997) Monochloramine-induced cell growth inhibition and apoptosis in a rat gastric mucosal cell line. J Clin Gastroenterol 25(Suppl 1):S179–S185CrossRefPubMed

20.

Suzuki H, Seto K, Mori M, Suzuki M, Miura S, Ishii H (1998) Monochloramine induced DNA fragmentation in gastric cell line MKN45. Am J Physiol 275(4 Pt 1):G712–G716PubMed

21.

Mishalian I, Bayuh R, Levy L, Zolotarov L, Michaeli J, Fridlender ZG (2013) Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression. Cancer Immunol Immunother 62(11):1745–1756. https://doi.org/10.1007/s00262-013-1476-9 CrossRefPubMed

22.

Fine N, Hassanpour S, Borenstein A, Sima C, Oveisi M, Scholey J, Cherney D, Glogauer M (2016) Distinct oral neutrophil subsets define health and periodontal disease states. J Dent Res 95(8):931–938. https://doi.org/10.1177/0022034516645564 CrossRefPubMed

23.

Beauvillain C, Delneste Y, Scotet M, Peres A, Gascan H, Guermonprez P, Barnaba V, Jeannin P (2007) Neutrophils efficiently cross-prime naive T cells in vivo. Blood 110(8):2965–2973. https://doi.org/10.1182/blood-2006-12-063826 CrossRefPubMed

24.

Daster S, Eppenberger-Castori S, Hirt C, Soysal SD, Delko T, Nebiker CA, Weixler B, Amicarella F, Iezzi G, Governa V, Padovan E, Mele V, Sconocchia G, Heberer M, Terracciano L, Kettelhack C, Oertli D, Spagnoli GC, von Holzen U, Tornillo L, Droeser RA (2015) Absence of myeloperoxidase and CD8 positive cells in colorectal cancer infiltrates identifies patients with severe prognosis. Oncoimmunology 4(12):e1050574. https://doi.org/10.1080/2162402X.2015.1050574 CrossRefPubMedPubMedCentral

25.

Droeser RA, Hirt C, Eppenberger-Castori S, Zlobec I, Viehl CT, Frey DM, Nebiker CA, Rosso R, Zuber M, Amicarella F, Iezzi G, Sconocchia G, Heberer M, Lugli A, Tornillo L, Oertli D, Terracciano L, Spagnoli GC (2013) High myeloperoxidase positive cell infiltration in colorectal cancer is an independent favorable prognostic factor. PLoS ONE 8(5):e64814. https://doi.org/10.1371/journal.pone.0064814 CrossRefPubMedPubMedCentral

26.

Sepe R, Piscuoglio S, Quintavalle C, Perrina V, Quagliata L, Formisano U, Terracciano LM, Fusco A, Pallante P (2016) HMGA1 overexpression is associated with a particular subset of human breast carcinomas. J Clin Pathol 69(2):117–121. https://doi.org/10.1136/jclinpath-2015-202907 CrossRefPubMed

27.

Bubendorf L, Nocito A, Moch H, Sauter G (2001) Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. J Pathol 195(1):72–79. https://doi.org/10.1002/path.893 CrossRefPubMed

28.

Xu B, Shen J, Guo W, Zhao W, Zhuang Y, Wang L (2019) Impact of the 2018 ASCO/CAP HER2 guidelines update for HER2 testing by FISH in breast cancer. Pathol Res Pract 215(2):251–255. https://doi.org/10.1016/j.prp.2018.10.035 CrossRefPubMed

29.

Piscuoglio S, Ng CK, Murray MP, Guerini-Rocco E, Martelotto LG, Geyer FC, Bidard FC, Berman S, Fusco N, Sakr RA, Eberle CA, De Mattos-Arruda L, Macedo GS, Akram M, Baslan T, Hicks JB, King TA, Brogi E, Norton L, Weigelt B, Hudis CA, Reis-Filho JS (2016) The genomic landscape of male breast cancers. clin cancer res 22(16):4045–4056. https://doi.org/10.1158/1078-0432.CCR-15-2840 CrossRefPubMedPubMedCentral

30.

Deyarmin B, Kane JL, Valente AL, van Laar R, Gallagher C, Shriver CD, Ellsworth RE (2013) Effect of ASCO/CAP guidelines for determining ER status on molecular subtype. Ann Surg Oncol 20(1):87–93. https://doi.org/10.1245/s10434-012-2588-8 CrossRefPubMed

31.

Ohara M, Matsuura K, Akimoto E, Noma M, Doi M, Nishizaka T, Kagawa N, Itamoto T (2016) Prognostic value of Ki67 and p53 in patients with estrogen receptor-positive and human epidermal growth factor receptor 2-negative breast cancer: validation of the cut-off value of the Ki67 labeling index as a predictive factor. Mol Clin Oncol 4(4):648–654. https://doi.org/10.3892/mco.2016.776 CrossRefPubMedPubMedCentral

32.

Gnant M, Harbeck N, Thomssen C (2017) St. Gallen/Vienna a brief summary of the consensus discussion about escalation and de-escalation of primary breast cancer treatment. Breast Care 12(2):102–107. https://doi.org/10.1159/000475698 CrossRefPubMedPubMedCentral

33.

Eruslanov EB, Bhojnagarwala PS, Quatromoni JG, Stephen TL, Ranganathan A, Deshpande C, Akimova T, Vachani A, Litzky L, Hancock WW, Conejo-Garcia JR, Feldman M, Albelda SM, Singhal S (2014) Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. J Clin Invest 124(12):5466–5480. https://doi.org/10.1172/JCI77053 CrossRefPubMedPubMedCentral

34.

Uribe-Querol E, Rosales C (2015) Neutrophils in cancer: two sides of the same coin. J Immunol Res 2015:983698. https://doi.org/10.1155/2015/983698 CrossRefPubMedPubMedCentral

35.

Scapini P, Lapinet-Vera JA, Gasperini S, Calzetti F, Bazzoni F, Cassatella MA (2000) The neutrophil as a cellular source of chemokines. Immunol Rev 177:195–203CrossRefPubMed

36.

Kousis PC, Henderson BW, Maier PG, Gollnick SO (2007) Photodynamic therapy enhancement of antitumor immunity is regulated by neutrophils. Cancer Res 67(21):10501–10510. https://doi.org/10.1158/0008-5472.CAN-07-1778 CrossRefPubMedPubMedCentral

37.

Dallegri F, Ottonello L, Ballestrero A, Dapino P, Ferrando F, Patrone F, Sacchetti C (1991) Tumor cell lysis by activated human neutrophils: analysis of neutrophil-delivered oxidative attack and role of leukocyte function-associated antigen 1. Inflammation 15(1):15–30CrossRefPubMed

38.

Di Carlo E, Forni G, Lollini P, Colombo MP, Modesti A, Musiani P (2001) The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood 97(2):339–345CrossRefPubMed

39.

Vanhamme L, Zouaoui Boudjeltia K, Van Antwerpen P, Delporte C (2018) The other myeloperoxidase: emerging functions. Arch Biochem Biophys 649:1–14. https://doi.org/10.1016/j.abb.2018.03.037 CrossRefPubMed

40.

Mika D, Guruvayoorappan C (2011) Myeloperoxidase: the yin and yang in tumour progression. J Exp Ther Oncol 9(2):93–100PubMed

41.

Trush MA, Kensler TW (1991) An overview of the relationship between oxidative stress and chemical carcinogenesis. Free Radic Biol Med 10(3–4):201–209CrossRefPubMed

42.

Pero RW, Sheng Y, Olsson A, Bryngelsson C, Lund-Pero M (1996) Hypochlorous acid/N-chloramines are naturally produced DNA repair inhibitors. Carcinogenesis 17(1):13–18CrossRefPubMed

43.

Kulcharyk PA, Heinecke JW (2001) Hypochlorous acid produced by the myeloperoxidase system of human phagocytes induces covalent cross-links between DNA and protein. Biochemistry 40(12):3648–3656CrossRefPubMed

44.

Van Rensburg CE, Van Staden AM, Anderson R, Van Rensburg EJ (1992) Hypochlorous acid potentiates hydrogen peroxide-mediated DNA-strand breaks in human mononuclear leucocytes. Mutat Res 265(2):255–261CrossRefPubMed

45.

Cui N, Hu M, Khalil RA (2017) Biochemical and biological attributes of matrix metalloproteinases. Prog Mol Biol Transl Sci 147:1–73. https://doi.org/10.1016/bs.pmbts.2017.02.005 CrossRefPubMedPubMedCentral

46.

Walters I, Austin C, Austin R, Bonnert R, Cage P, Christie M, Ebden M, Gardiner S, Grahames C, Hill S, Hunt F, Jewell R, Lewis S, Martin I, David N, David R (2008) Evaluation of a series of bicyclic CXCR46 antagonists. Bioorg Med Chem Lett 18(2):798–803CrossRefPubMed

47.

Quigley JP, Deryugina EI (2012) Combating angiogenesis early: potential of targeting tumor-recruited neutrophils in cancer therapy. Future Oncol 8(1):5–8. https://doi.org/10.2217/fon.11.133 CrossRefPubMed

48.

Ginestier C, Liu S, Diebel ME, Korkaya H, Luo M, Brown M, Wicinski J, Cabaud O, Charafe-Jauffret E, Birnbaum D, Guan JL, Dontu G, Wicha MS (2010) CXCR48 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest 120(2):485–497. https://doi.org/10.1172/JCI39397 CrossRefPubMedPubMedCentral

49.

Giraudo E, Inoue M, Hanahan D (2004) An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 114(5):623–633. https://doi.org/10.1172/JCI22087 CrossRefPubMedPubMedCentral

50.

Deryugina EI, Zijlstra A, Partridge JJ, Kupriyanova TA, Madsen MA, Papagiannakopoulos T, Quigley JP (2005) Unexpected effect of matrix metalloproteinase down-regulation on vascular intravasation and metastasis of human fibrosarcoma cells selected in vivo for high rates of dissemination. Cancer Res 65(23):10959–10969. https://doi.org/10.1158/0008-5472.CAN-05-2228 CrossRefPubMed

51.

Fingleton B (2008) MMPs as therapeutic targets–still a viable option? Semin Cell Dev Biol 19(1):61–68. https://doi.org/10.1016/j.semcdb.2007.06.006 CrossRefPubMed

52.

Clynes R (2006) Antitumor antibodies in the treatment of cancer: Fc receptors link opsonic antibody with cellular immunity. Hematol Oncol Clin North Am 20(3):585–612. https://doi.org/10.1016/j.hoc.2006.02.010 CrossRefPubMed

53.

Matsubara N, Mukai H, Itoh K, Nagai S (2011) Prognostic impact of Ki-67 overexpression in subgroups categorized according to St. Gallen with early stage breast cancer. Oncology 81(5–6):345–352. https://doi.org/10.1159/000334920 CrossRefPubMed

54.

Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ, Panel M (2011) Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22(8):1736–1747. https://doi.org/10.1093/annonc/mdr304 CrossRefPubMedPubMedCentral

Titel: Infiltration by myeloperoxidase-positive neutrophils is an independent prognostic factor in breast cancer
verfasst von: Jasmin Zeindler
Fiorenzo Angehrn
Raoul Droeser
Silvio Däster
Salvatore Piscuoglio
Charlotte K. Y. Ng
Ergin Kilic
Robert Mechera
Samuel Meili
Andrej Isaak
Walter P. Weber
Simone Muenst
Savas Deniz Soysal
Publikationsdatum: 02.07.2019
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 3/2019
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-019-05336-3

Springer Medizin

Infiltration by myeloperoxidase-positive neutrophils is an independent prognostic factor in breast cancer